BATRK vs MSGS: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
MSGS is the larger of the two ($9.39B market cap): the incumbent the market prices for continued execution (-631.95x forward earnings, beta 0.58). BATRK is the smaller challenger ($3.21B), priced similarly on forward earnings (-85.33x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BATRK vs MSGS: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BATRK | MSGS | What it tells you |
|---|---|---|---|
| Market cap | $3.21B | $9.39B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -85.33 | -631.95 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.82 | 0.58 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 79% of range | 90% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how BATRK and MSGS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BATRK and MSGS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BATRK and MSGS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Atlanta Braves Holdings (BATRK) do?
Atlanta Braves Holdings, Inc. was split off from Liberty Media in July 2023 and now trades on its own. It reports two segments. Baseball covers the Atlanta Braves club: ticketing, concessions, retail, sponsorship, local and national media rights, MLB's central revenue distributions and postseason economics. Mixed-Use Development covers The Battery Atlanta, the retail, restaurant, office, hotel and entertainment district the company built around Truist Park in Cobb County, Georgia. Revenue was roughly $750 million on a trailing twelve month basis through the second quarter of 2026, up from about $733 million in fiscal 2025 and about $663 million in 2024. The company employs roughly 1,450 people and is led by chairman and CEO Terence McGuirk.
What does Madison Square Garden Sports (MSGS) do?
Madison Square Garden Sports Corp. owns and operates the New York Knickerbockers of the NBA and the New York Rangers of the NHL, along with two development-league affiliates and a professional sports team performance business. Its revenue comes from ticket sales and premium seating, local media rights fees, sponsorship and signage, food and merchandise at games, and its share of leaguewide national media and licensing money. The company does not own Madison Square Garden itself: the arena sits inside MSG Entertainment, and the Knicks and Rangers pay to play there under long-term arrangements, which is why the reported financials look thinner than the size of the underlying assets suggests. Revenue for the trailing twelve months is roughly ~$1.08 billion against a market capitalization of about ~$9.4 billion, a ratio that only makes sense once you treat the company as an asset holder rather than an operating business.
BATRK vs MSGS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BATRK drivers: BravesVision and control of the media rights; The Battery Atlanta keeps compounding.
- MSGS drivers: Franchise scarcity; The proposed Knicks and Rangers separation.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The collective bargaining agreement between MLB and the players' union expires on December 1, 2026, and a work stoppage or a structural change such as a salary cap would directly affect both revenue and the cost base. For MSGS, the Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management.
BATRK or MSGS: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BATRK if you believe its drivers more; MSGS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BATRK and MSGS guides.
BATRK vs MSGS: the full fundamentals
BATRK. Because the company is not profitable on a GAAP basis, conventional earnings multiples do not apply, and management steers to Adjusted OIBDA and to segment revenue instead. Analysts and investors generally frame the stock against private sports franchise transaction values plus the appraised value of The Battery Atlanta, then subtract debt, which is a very different exercise from valuing an operating company on cash earnings. Seasonality is extreme: nearly all baseball revenue lands in the second and third quarters, so a single quarter read in isolation is misleading.
MSGS. Conventional earnings multiples do not describe this stock: the company runs near breakeven on an accounting basis while holding assets appraised at several times its revenue. The more common framework is a sum-of-the-parts, comparing the market capitalization of about ~$9.4 billion against combined franchise appraisals near ~$13.5 billion and then adjusting for borrowings and for the discount attached to a controlled structure. That gap has narrowed considerably over the past year as the shares roughly doubled off a 52-week low near ~$189, so the spin-off outcome now carries more of the weight than the raw appraisal spread does.
Headline figures (approximate, August 2026): BATRK shows market cap (all share classes) ~$3.1B, revenue (ttm through q2 2026) ~$750M, q2 2026 revenue ~$305M, down ~2% year over year, q2 2026 adjusted oibda ~$12M; MSGS shows share price ~$390, market capitalization ~$9.4 billion, revenue (ttm) ~$1.08 billion, net income (ttm) ~-$22 million (EPS ~-$0.93).
The bottom line: BATRK vs MSGS
BATRK and MSGS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BATRK and MSGS exposure against your real portfolio. It is not an investment adviser.
Wondering how BATRK or MSGS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Atlanta Braves Holdings with AI
Connect the broker you already use and ask Walnut's AI how BATRK fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between BATRK and MSGS?
+
Atlanta Braves Holdings, Inc. Madison Square Garden Sports Corp. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BATRK or MSGS the better stock?
+
Neither is universally better. MSGS is the larger incumbent; BATRK is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BATRK or MSGS?
+
On forward P/E (as of August 2026), BATRK trades at -85.33x and MSGS at -631.95x, so MSGS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BATRK and MSGS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BATRK vs MSGS?
+
BATRK: The collective bargaining agreement between MLB and the players' union expires on December 1, 2026, and a work stoppage or a structural change such as a salary cap would directly affect both revenue and the cost base. Major league player payroll has been the single largest driver of the company's operating expense growth, and it is largely committed years in advance regardless of results. The company reports GAAP losses, with an operating loss of roughly $71 million and a net loss of roughly $64 million on a trailing twelve month basis, so there is no earnings multiple to anchor to and results are highly seasonal, with the first and fourth quarters structurally loss-making. BravesVision is unproven as a standalone business and carries subscriber and cost risk that a fixed rights fee did not. Finally, the business is concentrated in one franchise and one real estate campus, and Series C holders have no votes, so governance rests with the voting classes and any control outcome is decided without them. MSGS: The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. The spin-off is exploratory: a confidential filing is not a commitment, and the transaction could be delayed, restructured or abandoned, in which case the narrowing of the discount could reverse. The company generates little in the way of reported profit (a trailing twelve-month net loss of about ~$22 million on ~$1.08 billion of revenue), so there is no earnings support underneath the price if franchise appraisals stop rising. Player compensation, collective bargaining outcomes and luxury-tax structures in both leagues can raise costs faster than revenue, and local media rights remain the softest part of the model. Finally, with roughly ~24 million shares outstanding, the float is small and the stock can move sharply on transaction headlines in either direction.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BATRK or MSGS; figures are approximate and dated (as of August 2026). Verify current data before investing.